SAR444200
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SAR444200 |
| Trade Name | |
| Synonyms | SAR-444200|SAR 444200 |
| Drug Descriptions |
SAR444200 is a nanobody T-cell engager that binds to both TCR alpha/beta and GPC3, directing cytotoxic T cells to GPC3-expressing tumors, potentially leading to T cell-dependent cellular toxicity (Ann Oncol (2023) 34 (suppl_2): S634). |
| DrugClasses | GPC3 Antibody 7 |
| CAS Registry Number | NA |
| NCIT ID | C199578 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + SAR444200 | Atezolizumab SAR444200 | 0 | 1 |
| Cemiplimab + SAR444200 | Cemiplimab SAR444200 | 0 | 0 |
| SAR444200 | SAR444200 | 0 | 1 |
CKB BOOST